Cerus Corporation (CERS)
After hours:
| Previous Close | 5.09 |
| Open | 5.29 |
| Bid | 5.04 x 3200 |
| Ask | 5.59 x 2900 |
| Day's Range | 5.14 - 5.43 |
| 52 Week Range | 4.35 - 8.06 |
| Volume | |
| Avg. Volume | 1,928,493 |
| Market Cap | 961.599M |
| Beta (5Y Monthly) | 1.07 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.29 |
| Earnings Date | Oct 31, 2022 - Nov 04, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.40 |
- Motley Fool
Cerus (CERS) Q2 2022 Earnings Call Transcript
Thank you for standing by, and welcome to the Cerus Corporation second quarter 2022 earnings conference call. With me on the call are Obi Greenman, Cerus' president and chief executive officer; Kevin Green, Cerus' chief financial officer; Vivek Jayaraman, Cerus' chief operating officer; Dr. Nina Mufti, Cerus' vice president, development, and red blood cell program Leader; Dr. Richard Benjamin, Cerus' chief medical officer; Carol Moore, Cerus' senior vice president of regulatory affairs and quality; and Jessica Hanover, Cerus' vice president of corporate affairs.
- Zacks
Cerus (CERS) Reports Q2 Loss, Tops Revenue Estimates
Cerus (CERS) delivered earnings and revenue surprises of 16.67% and 2.50%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Cerus Corporation Announces Another Record Quarter and Reiterates Full Year 2022 Product Revenue Guidance Range
CONCORD, Calif., August 04, 2022--Cerus Corporation (Nasdaq: CERS) today announced financial results for the second quarter ended June 30, 2022.
